Syros Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of right-of-use asset
Gain on disposal of fixed assets and modification of lease
Non-cash lease expense
Impairment of long-lived assets
Transaction costs allocated to warrants issued in connection with private placement
Loss on disposal of fixed assets
Stock-based compensation expense
Change in fair value of warrant liabilities
Net amortization of premiums and discounts on marketable securities
Amortization of debt-discount and accretion of deferred debt costs

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts receivable
Unbilled receivable
Other long-term assets
Accounts payable
Accrued expenses
Deferred revenue
Proceeds for tenant improvement incentive from landlord
Operating lease asset and liabilities
Operating lease liabilities

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from the disposition of property and equipment
Purchases of marketable securities
Maturities of marketable securities
Net cash provided by (used in) investing activities
Financing activities
Payments on financing lease obligations
Proceeds from issuance of common stock through exercise of warrants
Proceeds from issuance of common stock through employee benefit plans
Proceeds from the issuance of common stock through employee stock purchase plan
Proceeds from the issuance of common stock through exercise of stock options
Payment to creditor related to debt modification
Proceeds from the issuance of common stock through exercise of warrants
Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs
Proceeds from term loan, net of issuance costs
Proceeds from issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance costs
Cash and cash equivalents acquired in connection with merger,net of issuance costs paid
Proceeds from issuance of common stock and accompanying warrants and pre-funded warrants in private placement, net of issuance costs
Proceeds from issuance of common stock and accompanying warrants in public offerings and private placements, net of issuance costs
Proceeds from issuance of common stock and warrants in public offerings, net of issuance costs
Cash paid in lieu of fractional shares due to the reverse stock split
Proceeds from issuance of convertible preferred stock and accompanying warrants in public offering, net of issuance costs
Payment of offering costs
Redemption of fractional shares due to the reverse stock split
Payment of issuance costs related to out of period offering
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, Beginning of year
Cash, cash equivalents and restricted cash, End of year
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for tax

Non-cash investing and financing activities:
Property and equipment received but unpaid as of period end
Asset acquired under operating lease
Assets acquired under financing lease
Deferred debt financing costs incurred but unpaid as of period end
Offering costs incurred but unpaid as of year end

Comments